ST Pharm Co.,Ltd. (237690.KQ)
KRW 84900.0
(-4.61%)
KRW 84900.0
(-4.61%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 141.98 Billion KRW | 68.39% |
| 2022 | 84.31 Billion KRW | 23.43% |
| 2021 | 68.31 Billion KRW | -22.64% |
| 2020 | 88.3 Billion KRW | 2684.56% |
| 2019 | 3.17 Billion KRW | 106.66% |
| 2018 | -47.59 Billion KRW | 34.05% |
| 2017 | -72.16 Billion KRW | -34.44% |
| 2016 | -53.67 Billion KRW | -273.87% |
| 2015 | 30.87 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 129.99 Billion KRW | 14.82% |
| 2024 Q1 | 113.21 Billion KRW | -20.26% |
| 2023 Q2 | 108.55 Billion KRW | 9.75% |
| 2023 Q4 | 141.98 Billion KRW | -21.15% |
| 2023 FY | 141.98 Billion KRW | 68.39% |
| 2023 Q1 | 98.9 Billion KRW | 17.3% |
| 2023 Q3 | 180.06 Billion KRW | 65.88% |
| 2022 Q3 | 115.26 Billion KRW | 11.61% |
| 2022 FY | 84.31 Billion KRW | 23.43% |
| 2022 Q4 | 84.31 Billion KRW | -26.84% |
| 2022 Q2 | 103.27 Billion KRW | 27.52% |
| 2022 Q1 | 80.98 Billion KRW | 18.55% |
| 2021 Q4 | 68.31 Billion KRW | -20.21% |
| 2021 Q1 | 108.59 Billion KRW | 24.24% |
| 2021 Q2 | 100.13 Billion KRW | -7.79% |
| 2021 Q3 | 85.62 Billion KRW | -14.5% |
| 2021 FY | 68.31 Billion KRW | -22.64% |
| 2020 Q1 | -35.86 Billion KRW | -1405.27% |
| 2020 FY | 88.3 Billion KRW | 2684.56% |
| 2020 Q4 | 87.4 Billion KRW | 803.23% |
| 2020 Q3 | -12.42 Billion KRW | -54.42% |
| 2020 Q2 | -8.04 Billion KRW | 77.56% |
| 2019 Q2 | -15.42 Billion KRW | 58.18% |
| 2019 Q3 | -11.91 Billion KRW | 22.79% |
| 2019 Q4 | 2.74 Billion KRW | 123.07% |
| 2019 Q1 | -36.89 Billion KRW | 22.49% |
| 2019 FY | 3.17 Billion KRW | 106.66% |
| 2018 Q1 | -80.07 Billion KRW | -10.96% |
| 2018 FY | -47.59 Billion KRW | 34.05% |
| 2018 Q3 | -56.91 Billion KRW | 18.31% |
| 2018 Q2 | -69.66 Billion KRW | 13.0% |
| 2018 Q4 | -47.59 Billion KRW | 16.37% |
| 2017 Q2 | -74.67 Billion KRW | 5.63% |
| 2017 Q1 | -79.13 Billion KRW | -43.77% |
| 2017 Q4 | -72.16 Billion KRW | 10.02% |
| 2017 FY | -72.16 Billion KRW | -34.44% |
| 2017 Q3 | -80.19 Billion KRW | -7.4% |
| 2016 Q4 | -55.03 Billion KRW | -3.33% |
| 2016 Q2 | -100.72 Billion KRW | -953.31% |
| 2016 Q1 | 11.8 Billion KRW | -61.76% |
| 2016 Q3 | -53.26 Billion KRW | 47.12% |
| 2016 FY | -53.67 Billion KRW | -273.87% |
| 2015 FY | 30.87 Billion KRW | 0.0% |
| 2015 Q4 | 30.87 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | 13.19 Billion KRW | -975.827% |
| Hyundai Bioscience Co., Ltd. | 3.73 Billion KRW | -3701.809% |
| ABL Bio Inc. | 15.87 Billion KRW | -794.459% |
| Cellid, Co., Ltd. | -1.38 Billion KRW | 10344.579% |